New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.

Kyverna Therapeutics, Inc.

Contributing Author

Recent Articles by Kyverna Therapeutics, Inc.

Jan-12	Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference KYTX GlobeNewswire
Jan-05	Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference KYTX GlobeNewswire
Dec-17	Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock KYTX GlobeNewswire
Dec-15	Kyverna Therapeutics Announces Proposed Public Offering of Common Stock KYTX GlobeNewswire
Dec-15	Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome KYTX GlobeNewswire
Dec-14	Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome KYTX GlobeNewswire
Nov-12	Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results KYTX GlobeNewswire
Nov-10	Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference KYTX GlobeNewswire
Nov-03	Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance KYTX GlobeNewswire
Oct-29	Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025 KYTX GlobeNewswire
Oct-25	Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025 KYTX GlobeNewswire
Oct-22	Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis KYTX GlobeNewswire
Sep-24	Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS KYTX GlobeNewswire
Sep-15	Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025 KYTX GlobeNewswire
Aug-28	Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event KYTX GlobeNewswire
Aug-25	Kyverna Therapeutics to Present at Upcoming Investor Conferences in September KYTX GlobeNewswire
Aug-12	Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results KYTX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.